Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the shelf-stable Microcyn^® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform enables the creation of a biocompatible solution containing active oxychlorine compounds. The solutions derived from the shelf-stable Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The technology has also demonstrated wound healing in chronic and acute wounds in clinical investigational studies. It has been commercialized outside of the United States for the treatment of infected wounds.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K.